Lyophilization formulation
This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.
1. A pharmaceutical kit comprising:
a lyophilized preparation of a compound of the following formula:
wherein
each of X, Y, and Z, independently, is C 1-5 alkylene or deleted;
R 1 is H, C 1-5 alkyl, OH, or NH 2 ;
R 2 is C 3-10 cycloalkyl or (C 1-5 alkyl)-NH—(C 3-10 cycloalkyl); and
R 3 is P(═O)(OH) 2 , P(═O)(OH)(OC 1-5 alkyl), P(═O)(OC 1-5 alkyl) 2 , S(═O) 2 (OH), S(═O) 2 C 1-5 alkyl, or S(═O) 2 Ph; and
a sealed container,
wherein the lyophilized preparation is disposed in the sealed container.
2. The pharmaceutical kit of claim 1 , wherein X is —CH 2 —, —CH 2 CH 2 — or —CH 2 CH 2 CH 2 — and Y is —CH 2 or deleted and Z is —CH 2 —.
3. The pharmaceutical kit of claim 1 , wherein R 1 is NH 2 ; and R 2 is (C 1-5 alkyl)-NH—(C 3-10 cycloalkyl).
4. The pharmaceutical kit of claim 1 , wherein R 3 is P(═O)(OH) 2 , P(═O)(OH)(OCH 2 CH 3 ), P(═O)(OCH 2 CH 3 ) 2 , S(═O) 2 OH, S(═O) 2 CH 3 , or S(═O) 2 Ph.
5. The pharmaceutical kit of claim 1 , wherein the lyophilized compound is one of the compounds shown below:
6. The pharmaceutical kit of claim 1 , further comprising a bulking agent.
7. The pharmaceutical kit of claim 6 , wherein the kit is free of a tonicity adjuster.
8. The pharmaceutical kit of claim 6 , wherein the kit is free of sodium chloride.
9. The pharmaceutical kit of claim 6 , wherein the bulking agent is mannitol or dextran.
10. The pharmaceutical kit of claim 9 , wherein X is —CH 2 —, —CH 2 CH 2 — or —CH 2 CH 2 CH 2 —; Y is —CH 2 — or deleted and Z is —CH 2 —; R 1 is NH 2 ; R 2 is (C 1-5 alkyl)-NH—(C 3-10 cycloalkyl).
11. The pharmaceutical kit of claim 1 , wherein R 3 is P(═O)(OH) 2 , P(═O)(OH)(OCH 2 CH 3 ), P(═O)(OCH 2 CH 3 ) 2 , S(═O) 2 OH, S(═O) 2 CH 3 , or S(═O) 2 Ph.
12. The pharmaceutical kit of claim 11 , wherein the lyophilized compound is one of the compounds shown below:
13. The pharmaceutical kit of claim 1 , further comprising a tonicity adjuster.
14. The pharmaceutical kit of claim 13 , wherein the tonicity adjuster is sodium chloride.
15. The pharmaceutical kit of claim 1 , further comprising a bulking agent and a tonicity adjuster, wherein the weight ratio between the compound, the bulking agent, and the tonicity adjuster is 1-25:10-50:0.01-6.
16. The pharmaceutical kit of claim 1 , further comprising a bulking agent and a tonicity adjuster, wherein the weight ratio between the compound, the bulking agent, and the tonicity adjuster is 1-50:0.01-50:0.01-0.9.
17. The pharmaceutical kit of claim 16 , wherein the lyophilized compound is one of the compounds shown below:
18. A process of making a lyophilized preparation of a compound having the following formula:
wherein
each of X, Y, and Z, independently, is C 1-5 alkylene or deleted;
R 1 is H, C 1-5 alkyl, OH, or NH 2 ;
R 2 is C 3-10 cycloalkyl or (C 1-5 alkyl)-NH—(C 3-10 cycloalkyl); and
R 3 is P(═O)(OH) 2 , P(═O)(OH)(OC 1-5 alkyl), P(═O)(OC 1-5 alkyl) 2 , S(═O) 2 (OH), S(═O) 2 C 1-5 alkyl, or S(═O) 2 Ph; and
the process comprising:
providing an aqueous solution containing the compound;
cooling the solution to a temperature between −80° C. and −10° C.; and
vacuuming the cooled solution between −80° C. and −10° C. for 15-100 hours, and then between −9° C. and 35° C. for 10-200 hours.
19. The process of claim 18 , wherein the aqueous solution further contains a bulking agent.
20. The process of claim 18 , wherein the aqueous solution further contains a tonicity adjuster.
21. The process of claim 18 , wherein the aqueous solution further contains bulking agent and a tonicity adjuster.
22. The process of claim 21 , wherein the bulking agent is mannitol or dextran and the tonicity adjuster is sodium chloride.
23. The process of claim 22 , wherein, before the cooling step, the aqueous solution contains 1-50 mg/ml of the compound based on its free base form, 0.01-50 mg/ml mannitol or dextran, and 0.01-6 mg/ml sodium chloride.
24. The process of claim 18 , wherein, before the cooling step, the aqueous solution is sterilized by micro-filtration.
25. A lyophilized preparation made by a process comprising:
providing an aqueous solution containing a compound of the following formula:
wherein
each of X, Y, and Z, independently, is C 1-5 alkylene or deleted;
R 1 is H, C 1-5 alkyl, OH, or NH 2 ;
R 2 is C 3-10 cycloalkyl or (C 1-5 alkyl)-NH—(C 3-10 cycloalkyl); and
R 3 is P(═O)(OH) 2 , P(═O)(OH)(OC 1-5 alkyl), P(═O)(OC 1-5 alkyl) 2 , S(═O) 2 (OH), S(═O) 2 C 1-5 alkyl, or S(═O) 2 Ph;
cooling the solution to a temperature between −80° C. and −10° C.; and
vacuuming the cooled solution between −80° C. and −10° C. for 15-100 hours, and then between −9° C. and 35° C. for 10-200 hours.
26. The lyophilized preparation of claim 25 , wherein, the process further comprises, before the cooling step, sterilizing the solution micro-filtration.